PNAA
NVO

Pictet North America Advisors’s Novo Nordisk NVO Stock Holding History

Pictet North America Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-73,549
Closed -$5.08M – 148
2025
Q2 		$5.08M Buy
73,549
+1,395
+2% +$94.9K 0.51% 47
2025
Q1 		$5.01M Buy
72,154
+16,030
+29% +$1.32M 0.5% 50
2024
Q4 		$4.83M Buy
56,124
+822
+1% +$88.9K 0.46% 58
2024
Q3 		$6.58M Buy
55,302
+85
+0.2% +$11.3K 0.65% 41
2024
Q2 		$7.88M Buy
+55,217
New +$7.32M 0.86% 36

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pictet North America Advisors's NVO Position: Q3 2025 in Review

Pictet North America Advisors sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 73,549 shares — an estimated $5.08M sold.

Pictet North America Advisors first reported a position in NVO in Q2 2024 and held it in 5 quarters. The position peaked at $7.88M in Q2 2024. 1,396 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Pictet North America Advisors reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Pictet North America Advisors sold 73,549 Novo Nordisk shares in Q3 2025, an estimated $5.08M.
  • Pictet North America Advisors first reported a position in Novo Nordisk in Q2 2024 and held it in 5 quarters.
  • Pictet North America Advisors's Novo Nordisk position peaked at $7.88M in Q2 2024.
  • 1,396 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Pictet North America Advisors's 13F filing for Q3 2025, filed 21 Oct 2025.